Quarterly ResultAug 6, 2026, 08:04 AM
Viatris Q2 Revenue $3.8B, Adjusted EBITDA $1.2B; Raises 2026 Guidance
AI Summary
Viatris Inc. reported second-quarter 2026 financial results, with Total Revenues reaching $3.8 billion, a 5% reported increase, and Adjusted EBITDA growing 10% to $1.2 billion. The company recorded a U.S. GAAP net loss of $119 million, primarily due to a non-cash charge related to the sale of Tyrvaya® rights. Viatris raised the midpoints of its 2026 financial guidance for all metrics, including Total Revenues and Adjusted EBITDA, and announced strategic divestments and capital returns to shareholders.
Key Highlights
- Total Revenues were $3.8 billion, up 5% reported year-over-year.
- Adjusted EBITDA was $1.2 billion, up 10% reported year-over-year.
- U.S. GAAP Net Loss was $119 million, compared to $4.6 million loss in Q2 2025.
- Raises 2026 Total Revenues guidance midpoint to $14.75 billion.
- Raises 2026 Adjusted EBITDA guidance midpoint to $4.4 billion.
- Sold global rights to Tyrvaya® for $30 million upfront plus $70 million in milestones.
- Completed sale of Biocon Limited equity for approximately $380 million pre-tax.
- Returned approximately $550 million to shareholders, including $270 million in buybacks.
Price Impact
More from VTRS